Open in App
  • U.S.
  • Election
  • Newsletter
  • targetedonc.com

    SEQUOIA Arm D Study: Zanubrutinib plus Venetoclax in Treatment-Naive CLL/SLL with del(17p) and/or TP53 Mutations

    By Mazyar Shadman, MD, MPH,

    1 day ago
    Comments / 0
    Add a Comment
    YOU MAY ALSO LIKE
    Most Popular newsMost Popular

    Comments / 0